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melanoma epigeneticsMelanoma is a highly aggressive cancer, accounting for up to 75% of skin cancer deaths. A small proportion of
melanoma cases can be ascribed to the presence of highly penetrant germline mutations, and approximately
40% of hereditary melanoma cases are caused by CDKN2A mutations. The current study sought to investigate
whether the presence of germline CDKN2Amutations or the occurrence of cutaneous melanoma would result
in constitutive genome-wide DNAmethylation changes. The leukocyte methylomes of two groups of melanoma
patients (thosewith germline CDKN2Amutations and thosewithout CDKN2Amutations)were analyzed together
with the proﬁle of a control groupof individuals. A pattern of DNAhypomethylationwas detected in theCDKN2A-
negative patients relative to both CDKN2A-mutated patients and controls. Additionally, we delineated a panel of
90 CpG sites that were differentially methylated in CDKN2A-mutated patients relative to controls. Although we
identiﬁed a possible constitutive epigenetic signature in CDKN2A-mutated patients, the occurrence of reported
SNPs at the detected CpG sites complicated the data interpretation. Thus, further studies are required to elucidate
the impact of these ﬁndings on melanoma predisposition and their possible effect on the penetrance of CDKN2A
mutations.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Melanoma is a rare but highly aggressive cancer, accounting for 75%
of skin cancer deaths (Schinke et al., 2010). The majority of melanoma
cases is sporadic, but approximately 10% are hereditary and arise from
highly penetrant germlinemutations (Ward et al., 2012). The full genet-
ic architecture underlying melanoma risk has not yet been elucidated,
but CDKN2A is well established as a high-risk susceptibility gene, also
known to increase the risk of pancreatic cancer (Udayakumar et al.,
2010). CDKN2A encodes two different tumor suppressor proteins
(p16INK4a and p14ARF), but the majority of the mutations affect
p16INK4a, accounting for approximately 40% of familial cases, most ofEvolutionary Biology, Institute
77, CEP: 05508-090, Sao Paulo,
ischi).
. This is an open access article underwhich present with multiple melanomas. A few families were also re-
ported to segregate germline mutations in either the p14ARF isoform
of CDKN2A or the CDK4 gene (Puntervoll et al., 2013; Tsao et al.,
2012). The penetrance of CDKN2Amutations is incomplete, depending
on age and geographic location; in addition, different clinical features
have been reported in patients from the same family (Hyland et al.,
2013). These observations indicate that additional genetic and environ-
mental factors are relevant to cancer development and progression in
individuals carrying CDKN2Amutations.
Epigenetic modiﬁcations can be deﬁned as changes in chromatin
that do not modify the underlying DNA sequence; these modiﬁcations
are stable and heritable yet reversible (Bonasio et al., 2010). Epigenetic
patterns serve as markers of gene activity as well as chromatin state
(Srivastava et al., 2010). One major epigenetic process is DNA methyla-
tion, a chemical modiﬁcation occurring mostly in CpG dinucleotides
(Goll and Bestor, 2005). DNAmethylation is an epigeneticmark control-
ling several biological processes, ranging from physiological conditionsthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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been extensively documented (Hesson et al., 2010; Sharma et al., 2010).
Epigenetic inactivation of CDKN2A is a common ﬁnding in melanomas
(Freedberg et al., 2008), and aberrantmethylation has also been report-
ed for other genes (Schinke et al., 2010), with only a few of them
exhibiting hypomethylation (Loriot et al., 2006).
It has been proposed that genetic mutations can lead to DNA meth-
ylation changes (Richards, 2006). The effects of mutations reach far be-
yond their aberrant genic product, as indicated by the genome-wide
methylation changes driven by BRAF mutation in melanoma cells
(Hou et al., 2011, 2012). In the scenario of cancer predisposition, the
ﬁrst example of germline epimutation was the MSH2 methylation
caused by deletion of the EPCAM gene in some Lynch syndrome patients
(Ligtenberg et al., 2009). Epimutation in melanoma predisposition was
investigated in some melanoma-prone families negative for CDKN2A
mutations, but germline hypermethylation of the CDKN2A promoter
was not detected (van Doorn et al., 2009).
Given the role of DNA methylation in tumorigenesis and the lack of
epigenetic studies related to melanoma predisposition, our goal was to
explorewhether the presence of germline CDKN2Amutations or the oc-
currence of cutaneous melanoma would lead to constitutive genome-
wide DNA methylation changes in melanoma patients. We identiﬁed a
possible constitutive epigenetic signature in CDKN2A-mutated patients,
and a pattern of DNA hypomethylation in CDKN2A-negative patients
relative to both CDKN2A-mutated patients and controls.
2. Patients and methods
2.1. Patients and control samples
This study was performed at the A. C. Camargo Cancer Center in Sao
Paulo, Brazil, and the ethics committee of the institution approved the
research protocol. Leukocyte DNA samples were obtained from periph-
eral blood, which was collected after the patients had signed informed
consent forms.
Melanoma patients were referred to the Skin Cancer Department of
the A. C. Camargo Cancer Center. The patients' personal and family his-
tories of cancer were recorded. The group of hereditary melanoma pa-
tients comprised 8 unrelated probands previously found to carry
pathogenic CDKN2A mutations (de Ávila et al., 2014; clinical data of
these patients can be found in the Supplementary data 1). All
CDKN2A-mutated patients were free of disease for at least one year
when the peripheral blood samples were collected.
Eight leukocyte DNA samples from sporadic melanoma patients
without detectable disease at the time of blood drawwere also included
in the study. This group of patients with sporadic melanoma was nega-
tive for CDKN2Amutations.Weused eight unrelated healthy individuals
as controls for the leukocytemethylome; these subjects were paired ac-
cording to sex and age with the CDKN2A-mutated patients. Further-
more, additional sporadic melanoma patients (n= 46) and control
individuals (n= 95) were genotyped for the SNP rs869047.
2.2. Genome-wide DNA methylation analysis
2.2.1. Inﬁnium HumanMethylation450K BeadChips
DNA methylation proﬁles of leukocytes were obtained using the
Inﬁnium HumanMethylation450K BeadChips (Illumina), following
the manufacturer's instructions. These microarrays interrogate the
DNA methylation status across 485,577 CpG loci distributed along
the genome at single-nucleotide resolution. Brieﬂy, a total of
500 ng bisulﬁte-converted DNA (EZ DNA methylation kit; Zymo Re-
search) from each sample was ampliﬁed, fragmented and hybridized
to BeadChips. Microarray images were captured using the iScan SQ
scanner (Illumina), and only experiments exhibiting the recom-
mended quality control parameters (call rate N0.98 of probes with
detection P-value ≤ 0.01) were used. Methylation data weredeposited into NCBI's Gene Expression Omnibus under the accession
number GSE54939 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE54939).
2.2.2. Differential methylation analysis
Probes lacking β-values in any sample and those mapped to
chromosomes X or Y were removed from the analysis. The raw data
were normalized as proposed by Touleimat and Tost (2012), incorpo-
rating the correction of the Inﬁnium II probe signals based on Inﬁnium I.
To identify methylation differences among sporadic melanoma pa-
tients, CDKN2A-mutated patients and individuals without a personal
history of cancer (controls), we performed statistical analysis with
SAM (Signiﬁcance Analysis of Microarrays, multi-class test with
delta = 0.5, 100 permutations, 90th percentile FDR= 0.49%), using
theβ-values of the top 1% of probes with the highest standard deviation
across all samples (4708 CpGs), including sporadic melanoma patients,
CDKN2A-mutated patients and controls.
In addition, we performed differential methylation analysis compar-
ing CDKN2A-mutated patients and control subjects. This analysis was
carried out after obtaining the delta-β values (Δβ) for each CpGmarker
by subtracting the mean β-value of the CDKN2A-mutated group from
the mean β-value of the control group. Next, a threshold of Δβ ≤
−0.20 or Δβ ≥ 0.20 was applied for selecting a set of CpGs, which
were submitted to the Rank Product (RP) statistical test using the
MultiExperiment Viewer (MeV) software (version 4.4.1), considering
100 permutations, a two-class test and FDR at 10%.
Hierarchical clusters were constructed for both analysis (SAM and
RP) for statistically signiﬁcant CpG sites using Euclidean distance and
average linkage.
Information about differentially methylated CpG sites was retrieved
from the dataset GSE42409 available at the Gene Expression Omnibus
(Price et al., 2013), which reports SNPs and repetitive elementsmapped
either at CpG targets or probe sequences. In order to consider the effect
of cellular heterogeneity of peripheral blood in the DNA methylation
variability, differentially methylated CpG sites were matched with
data provided by Jaffe and Irizarry (2014). Ingenuity Pathway Analysis
(IPA) software was used for in silico analysis of the set of differentially
methylated genes. Networks were obtained using the core analysis
tool, considering the Ingenuity knowledgebase (genes + endogenous
chemicals), the human species, melanoma cell lines and all types of tis-
sues and primary cells. We selected for presentation those networks
with the highest scores.
2.3. Quantitative bisulﬁte pyrosequencing
Technical validation of the methylation level of a single CpG site
(cg00631877;mapped to the PLXNC1 gene)was performedby quantita-
tive bisulﬁte pyrosequencing using PyroMark Q96 ID (Qiagen). PCRwas
performed using the PyroMark PCR kit (Qiagen) according to the
manufacturer's instructions. The following primer sequences were
used: F-[Btn]AGGAGGTTGGTGGGTTAG, R-CCACCAATTACCTCTTCC,
Sequencing-TATACTCTAATATCA. After DNA bisulﬁte-converted ampliﬁ-
cation (input of 20–40 ng), biotinylated PCR products were precipitated
using streptavidin-sepharose (GE Healthcare), and DNA strands were
separated with PyroMark denaturation solution (Qiagen). Next, the
samples were prepared in the PyroMark Q96 VacuumWorkstation for
primer sequencing, annealed and submitted to pyrosequencing with
PyroMark Gold Q96 reagents (Qiagen).
2.4. Genotyping of SNPs at CpG site
Four SNPs located at CpG sites were genotyped: cg00631877
(PLXNC1, rs869047), cg25709790 (DFNA5, rs2240005), cg13167158
(MIB2, rs11544452) and cg13078798 (TGFBR3, rs11165390). The list
of primers and PCR conditions are available upon request. PCR products
were sequenced using the BigDye® Terminator v3.1 Cycle Sequencing
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in 3130xl Genetic Analyzer, following manufacturer's instructions (Ap-
plied Biosystems).
3. Results
SAM analysis comparing the top 1% most variable probes among
sporadic melanoma patients, CDKN2A-mutated melanoma patients
and controls resulted in 166 differentially methylated CpGs (Supple-
mentary data 2). Hierarchical clustering showed that the group of spo-
radic melanoma patients had a distinctly hypomethylated methylome
when compared to the two other groups (Fig. 1A). Part of this set of dif-
ferentially methylated sites (115 CpGs) was mapped within sequences
related to 110 genes, four of which had already been linked to melano-
ma: NRAS, CDH5, SK1 and GRIN2A. The presence of SNPs and repetitive
elements overlapping the full CpGdataset (166CpGs)was investigated;
4.2% of the differentially methylated CpG sites were found to harbor
SNPs at either cytosine or guanine, and 18.7% of the probes contained re-
petitive DNA in their sequences. Additionally, 130 of this set of 166
hypomethylated CpGs are sites that presentmethylation level varying ac-
cording to the type of blood cells (see Supplementary data 2). In conclu-
sion, this analysis showed that sporadic melanoma patients exhibit a
global DNA hypomethylation proﬁle compared to both CDKN2A-
mutated patients and controls, which is mostly related to non-
repetitive sequences.
This group of 110 hypomethylated genes was then evaluated using
the network analysis tool of the IPA software. The top three canonical
pathways among all differentially methylated genes included Telomere
Extension by Telomerase, Molecular Mechanisms of Cancer and CDK5
Signaling. The most relevant of the created networks connected 21 of
these genes harboring differentially methylated CpG sites with 10 addi-
tional genes, and this network was related to Embryonic Development,
Organ Development and Organismal Development (Supplementary
data 3, Figure S1A). In this network, the NRAS gene appeared to play a
central role. Another network, involving 20 of the differentially methyl-
ated genes, was related to Hair and Skin Development and Function,
Organ Morphology and Digestive System Development and Function
(Supplementary data 3, Figure S1B).
To identify DNAmethylation differences that might be driven by the
presence of germline CDKN2A mutations, the methylation status ofFig. 1. Hierarchical clustering of the set of differentially methylated CpG sites in melanoma pat
(A) SAM statistical analysis revealed a panel of 166 hypomethylated CpG sites in sporadic
(B) RP statistical analysis identiﬁed a set of 47 CpG sites that were hypomethylated in CD
methylation level.CDKN2A-mutated patients was interrogated relative to that of the con-
trol group. We selected 589 differentially methylated CpGs (0.20 ≤ Δβ
or Δβ ≤ −0.20), which were submitted to Rank Products statistical
analysis. Ninety CpG sites differed signiﬁcantly between groups (47
hypomethylated and 43 hypermethylated, Table 1), and 63 of them
mappedwithin 58 genes or their regulatory sequences. In the hierarchi-
cal clustering analysis, only the group of hypomethylated CpGs could
distinguish the CDKN2A-mutated patients from the controls (Fig. 1B).
The presence of SNPs and repetitive elements overlapping this CpG
dataset was investigated, and the results indicated that 87.8% of the 90
CpG sites harbored a putative SNP at the cytosine or guanine, and
18.9% of the probesmapped fully or partially at repetitive DNA elements
(Table 1). Using one of these CpG sites, we performed a technical valida-
tion by quantitative bisulﬁte pyrosequencing. The obtainedmethylation
level of the cg00631877 probe, mapped within the PLXNC1 gene, was
highly correlated with 450 K microarray data (Spearman's correlation
coefﬁcient of 0.85; see Supplementary data 4). To investigate the pres-
ence of SNPs at the detected differentially methylated CpGs, we geno-
typed four sites in CDKN2A-mutated patients' and controls': the
cg00631877, and three additional CpG sites (Table 2). Methylation
levels measured using the 450K microarrays are directly associated
with the genotype: the abolishment of CpG siteswas associated to hypo-
methylation and, conversely, the hypermethylation was associated to
the CpG site maintenance. We verify the allele frequency at rs869047
(cg00631877) in a larger group of melanoma patients (n= 62) and con-
trols (n= 95), and no statistically signiﬁcant difference was observed
between groups (Fisher's exact test, P= 0.196). In summary, we found
a signature distinguishing CDKN2A-mutated patients from control sub-
jects, whichwasmostly related to unique sites harboring putative SNPs.
The affected set of 58 differentially methylated genes was then eval-
uated using IPA. Two relevant networks were generated, one of which
included 14 genes fromour set, andwas associatedwith Connective Tis-
sue Disorders, Developmental Disorders and Hereditary Disorders; in
this network, the gene DYSF was connected to several other genes.
The second relevant network contained 14 genes from our dataset and
showed functions related to Cell-To-Cell Signaling and Interaction, He-
matological System Development and Function and Immune Cell Traf-
ﬁcking (Fig. 2). The top disease in this analysis was cancer, containing
26 genes from the group of detected differentially methylated genes
(marked in Table 1).ients.
melanoma patients compared to CDKN2A-mutated patients and controls.
KN2A-mutated melanoma patients compared to controls. Color boxes at right indicate the
Table 1
Differentially methylated CpG sites in melanoma patients carrying CDKN2Amutations compared to the control group of healthy individuals.
Illumina target ID Chromosome Genomic coordinates (Hg19) Δβ P-value Genea SNP at the target CpG siteb Repetitive elementsa,b
cg15150396 2 71787431 −0.57 3.2e−4 DYSFc rs11896175 –
cg12466610 1 220950205 −0.51 b1e−6 MARC2 rs12402066 –
cg00030117 2 119980249 −0.49 0.002 STEAP3c rs838059 –
cg21927991 8 135494242 −0.48 0.002 ZFATc rs5025124 –
cg16377948 1 113221657 −0.46 0.002 MOV10 rs2999155 –
cg09866143 3 124861521 −0.46 0.003 SLC12A8c rs11917613 MER5A1
cg00631877 12 94640673 −0.44 0.004 PLXNC1c rs869047 –
cg26846609 16 20750043 −0.43 0.002 THUMPD1 rs1466770 –
cg03549208 2 203642154 −0.42 0.002 ICA1L rs62194158 –
cg09636756 18 77134251 −0.42 4.2e−4 ATP9Bc rs3786181 –
cg02627240 7 144184387 −0.42 0.02 TPK1 rs41237 –
cg04515524 19 17489148 −0.39 0.009 PLVAP rs73018403, rs7258084 –
cg07258715 3 12801785 −0.38 0.012 TMEM40 rs9865548 LINE
cg24051749 1 39340282 −0.38 8.65e−4 GJA9c;MYCBP rs880303 –
cg05308244 12 130968528 −0.37 0.009 RIMBP2c rs4320987 –
cg04990378 20 61160996 −0.37 0.005 C20orf166c;MIR133A2 rs6143047 –
cg04145681 6 30899162 −0.36 0.002 SFTA2 rs2532925 –
cg24407607 6 116753994 −0.35 0.008 DSE rs549262 –
cg21589417 2 170834853 −0.34 0.009 UBR3 rs13017065 LINE
cg17040924 11 4565489 −0.33 0.015 OR52M1c rs2641412 –
cg27341708 4 140952109 −0.33 0.015 MAML3c rs11100449 –
cg24844518 5 156811669 −0.31 0.009 CYFIP2 rs4305634 –
cg13815695 12 104237895 −0.31 0.002 GNN rs7966100 –
cg13653328 5 148520669 −0.31 0.007 ABLIM3c,d rs11168092 –
cg04246708 1 246785611 −0.30 0.015 CNST rs3129547 –
cg10776061 19 12768390 −0.30 0.004 MAN2B1 rs73002392 –
cg23803868 19 2340235 −0.26 0.004 SPPL2B rs12460384 –
cg05809586 21 31709690 −0.22 0.007 KRTAP27-1c rs2244485 –
cg24087071 14 94750291 0.51 b1e−6 SERPINA10c rs1950641 –
cg25709790 7 24742552 0.51 4.1e−4 DFNA5 rs2240005 –
cg22142142 15 90891614 0.49 0.001 GABARAPL3 rs6496665 –
cg07157030 14 63671356 0.49 0.005 RHOJc – –
cg13167158 1 1562535 0.46 0.001 MIB2 rs11544452 –
cg24086348 17 67138138 0.46 0.002 ABCA6c rs3744489 –
cg18771300 14 63671737 0.46 0.011 RHOJc – –
cg10926851 5 146253830 0.45 1.7e−5 PPP2R2Bc rs1835950 LINE
cg09167828 2 11286089 0.44 0.002 C2orf50 rs11903207 SINE
cg05751055 6 33036504 0.42 0.002 HLA-DPA1c rs1042434 –
cg13078798 1 92203667 0.41 0.005 TGFBR3c rs11165390 LTR
cg14302130 6 33032830 0.40 0.002 HLA-DPA1c rs1042920 –
cg20981163 6 33049983 0.40 0.003 HLA-DPB1 rs9277358, rs75339520 –
cg10528826 7 157571460 0.39 0.006 PTPRN2c rs28448886 –
cg12012426 4 1366463 0.39 0.002 UVSSAc rs6856550 –
cg11716267 2 24367828 0.39 0.003 LOC375190 rs35331966 LINE
cg11437465 6 33036958 0.38 0.011 HLA-DPA1c rs2308929 –
cg06484169 6 33052354 0.38 0.012 HLA-DPB1 rs9277441, rs80340467 SINE
cg14516100 4 186560083 0.37 0.012 SORBS2c – –
cg10500653 1 39407651 0.36 0.005 RHBDL2 – –
cg05876883 16 58704495 0.36 0.006 SLC38A7 rs16960359 –
cg25283336 6 33033484 0.35 0.016 HLA-DPA1c rs67640541 –
cg12858166 6 33033176 0.35 0.007 HLA-DPA1c – –
cg11738485 19 12877000 0.35 0.008 HOOK2 – –
cg16523115 3 136675725 0.34 0.012 IL20RB rs73864647 LINE
cg13431688 9 101869277 0.33 0.006 TGFBR1c rs6478972 –
cg20550012 7 157370486 0.33 0.012 PTPRN2c rs123779 –
cg10771931 19 34972145 0.30 0.0135 WTIP rs7248847 –
cg07878625 7 148977647 0.30 0.008 ZNF783 rs10248661 –
cg10993865 13 111293846 0.29 0.011 CARS2 rs330570 –
cg01600516 17 6904263 0.27 0.015 ALOX12c rs11571335 –
cg01543583 14 59947673 0.27 0.005 C14orf149 rs1253100 –
cg16652920 1 7432614 0.23 0.005 CAMTA1c rs11579620 –
cg21598190 7 2099404 0.23 0.010 MAD1L1c rs6953670 –
cg08136432 16 88902276 0.21 0.012 GALNS rs12934499, rs17603837 –
cg02100397 19 646890 −0.50 1.9e−4 – rs10403235 –
cg11331837 17 35161825 −0.44 0.001 – rs295848 –
cg19373347 1 219634786 −0.42 0.005 – rs12025363 –
cg06445586d 11 49073835 −0.41 0.007 – – –
cg12074150 2 34128722 −0.41 3.2e−4 – rs2103033, rs1705134 LTR
cg12479705 4 13893547 −0.37 0.007 – rs962301 –
cg22849321 6 113128231 −0.37 0.011 – rs3844153 LINE
cg08717807 16 85531414 −0.35 0.005 – rs9931008 –
cg16032108 11 2286079 −0.33 0.007 – – MER45B
cg00727777 8 2337813 −0.32 0.010 – – –
cg22305850 2 100824103 −0.32 0.01 – rs4851267 –
cg10470368 11 64146517 −0.31 0.011 – rs61886927 MER45B
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Table 1 (continued)
Illumina target ID Chromosome Genomic coordinates (Hg19) Δβ P-value Genea SNP at the target CpG siteb Repetitive elementsa,b
cg21070081 5 110105162 −0.31 0.001 – rs244431 –
cg24643105 11 113928473 −0.30 0.007 – rs34029763 –
cg19300401 6 16962712 −0.29 0.002 – rs6903672 LINE
cg27452255 1 85686316 −0.29 0.01 – rs12563295 –
cg19384241 2 55393977 −0.29 0.005 – – –
cg26941787 12 76023400 −0.28 0.006 – rs7958760 LINE
cg25649515 3 177309023 −0.23 0.014 – rs552757 –
cg27225663 6 169142715 0.51 0.003 – rs909507 Simple repeat
cg16992599 15 28752121 0.44 0.004 – – –
cg14797147 5 124309096 0.41 8.5e−4 – rs62372824 –
cg03965172 4 3683268 0.36 0.012 – rs2880892 –
cg26465155 11 35611044 0.36 0.009 – rs610680 LTR
cg11857805 14 100441223 0.34 0.004 – rs1191030 –
cg18557837 3 39847605 0.28 0.009 – rs9858242 –
cg21587006 10 839609 0.27 0.01 – rs61831437 –
Δβ = [(mean β-value of CDKN2A-mutated group) − (mean β-value of control group)].
a UCSC Genome Browser.
b According to Price et al. (2013).
c Genes related to cancer (Ingenuity Pathway Analysis).
d Sites that present variable methylation level according to the type of blood cells Jaffe and Irizarry (2014).
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This study reports the ﬁrst genome-wide DNAmethylation proﬁling
of leukocytes in melanoma patients. In particular, the methylation pro-
ﬁle ofmelanomapatients carrying CDKN2Amutationswas analyzed rel-
ative to that of individuals without a personal history of cancer to
determine whether germline mutations affecting a cancer gene could
lead to epigenomic changes. Additionally, we included a group of
CDKN2A-negative sporadic melanoma patients to identify DNAmethyl-
ation marks possibly related to the occurrence of melanoma.
Our results showed that sporadic melanoma patients exhibited a
hypomethylated proﬁle relative to both CDKN2A-mutated patients and
control subjects. The hypomethylation of this set of genes represents a
possible epigenetic mark resulting from previous cancer occurrence
and includes genes known to be relevant for melanoma. NRAS, an onco-
gene that is mutated in more than 20% of melanomas (Fedorenko et al.,
2013), was highlighted in the identiﬁed network as playing a key role,
similar to the CDH5 gene, which is overexpressed in aggressivemelano-
ma cells (Hendrix et al., 2001). In addition, previous studies have iden-
tiﬁed SKI as a tumor suppressor and tumor-promoting gene (Reed et al.,Table 2
Genotyping of SNPs at differentially methylated CpG sites in melanoma patients carrying
CDKN2Amutations relative to control group of healthy individuals.
Sample
ID
PLXNC1 DFNA5 MIB2 TGFBR3
rs869047
(β-value)
rs2240005
(β-value)
rs11544452
(β-value)
rs11165390
(β-value)
[G; 0.441]a [G; 0.425]a [G; 0.240]a [G; 0.460]a
Mel.M1 NA (0.56) NA (0.87) NA (0.97) NA (0.42)
Mel.M2 A/G (0.59) A/G (0.44) G (0.94) G (0.83)
Mel.M3 A (0.06) G (0.88) G (0.95) A/G (0.52)
Mel.M4 A/G (0.54) G (0.89) G (0.96) G (0.86)
Mel.M5 A (0.05) G (0.88) G (0.96) G (0.88)
Mel.M6 A/G (0.57) G (0.90) A/G (0.24) G (0.84)
Mel.M7 A (0.06) G (0.89) G (0.96) A (0.07)
Mel.M8 A/G (0.57) G (0.92) G (0.93) G (0.82)
C1 A/G (0.63) A/G (0.31) G (0.95) A/G (0.40)
C2 G (0.89) A (0.02) A/G (0.23) A (0.06)
C3 G (0.92) A (0.04) A/G (0.22) A (0.07)
C4 A/G (0.60) A/G (0.39) A/G (0.21) A (0.07)
C5 G (0.92) A (0.04) G (0.95) G (0.81)
C6 G (0.93) A/G (0.44) A/G (0.25) A (0.05)
C7 A/G (0.68) A/G (0.46) A/G (0.21) A (0.07)
C8 G (0.94) G (0.89) A/G (0.20) A/G (0.46)
NA — information not available.
Mel.M1-8:melanoma patients carrying CDKN2A mutations C1-8: healthy individuals
a [Ancestral allele; heterozygosity] according to NCBI dbSNP BUILD 138.2005), and GRIN2A as frequently mutated in melanoma and related to
cancer progression (Prickett and Samuels, 2012; Wei et al., 2011).
Preceding studies have investigated the DNAmethylation pattern of
the peripheral blood in patients with several types of cancers, in an ef-
fort to search for relevant biomarkers (Koestler et al., 2012; Langevin
et al., 2012; Marsit et al., 2011; Pedersen et al., 2011; Schinke et al.,
2010; Teschendorff et al., 2009; Wang et al., 2010). Koestler and co-
workers (2012) suggested that the detected methylation differences
were due to changes in leukocyte subpopulations during the course of
the disease. We did not detect differentially methylated CpG sites over-
lapping the top 50 sites proposed as a leukocyte signature of cancer pa-
tients. Therefore, melanoma patients may show a distinctive DNA
methylation proﬁle in their peripheral blood compared to other cancer
patients.
In a meta-analysis study, Woo and Kim (2012) proposed that DNA
hypomethylation may be a suitable biomarker for cancer risk. Accord-
ingly, it was recently shown that this hypomethylationmight be advan-
tageous for cancer development (Friso et al., 2013). However, CDKN2A-
mutatedmelanomapatients did not showextensiveDNAhypomethyla-
tion, suggesting that the detecteddifference inmethylation proﬁlesmay
reﬂect differences in the genetic etiology of themelanoma between the
two groups (sporadic versus hereditary melanoma). Alternatively, it is
possible that the distinct hypomethylation patterns resulted from the
different time periods that elapsed from the occurrence of the cancer
until the leukocytes of the melanoma patients with and without
CDKN2A mutations were collected. According to Jaffe and Irizarry
(2014), the cellular composition of peripheral blood is a source of vari-
ability in DNAmethylation. Thus, the occurrence of melanomamay lead
to differences in the composition of blood cell populations, resulting in
broad changes in the DNA methylation proﬁle of leukocytes that
would eventually decrease in frequency over time. In our study, al-
though the group of sporadicmelanomapatients was free of the disease
at the time of blood draw, it still showed a hypomethylated DNAmeth-
ylation proﬁle. However, about 80% of the detected hypomethylated
CpGswere sites highlighted as variable according to leukocyte cell com-
position (Jaffe and Irizarry, 2014), suggesting that the detected
hypomethylated proﬁle can represent differences in cell composition
as a result of the short time elapsed from the occurrence of the disease.
We also delineated a panel of CpG sites that distinguished CDKN2A-
mutated melanoma patients from controls, suggesting an epigenetic
signature associated with the presence of germline CDKN2Amutations.
The gene SDC2 was suggested as an upstream regulator based on IPA
analysis, and it is noteworthy that this gene is regulated by MC1R, a
key gene involved in melanogenesis (Chung et al., 2012). Nevertheless,
the majority of sites from the panel of differentially methylated CpGs
Fig. 2.Networks created by IPA based on the interactions between the set of 58 differentiallymethylated genes in CDKN2A-mutatedmelanoma patients relative to control individuals. The
two most relevant networks were associated with the following pathways:
(A) Connective Tissue Disorders, Developmental Disorders and Hereditary Disorders, in which the gene DYSF appeared to play a central role;
(B) Cell-To-Cell Signaling and Interaction, Hematological SystemDevelopment and Function and Immune Cell Trafﬁcking. The intensity of the node color indicates the degree of DNA
methylation. Uncolored nodes are genes incorporated by IPA based on scientiﬁc evidence
430 É.S.S. de Araújo et al. / Experimental and Molecular Pathology 97 (2014) 425–432harbored putative SNPs, and this complicated the data interpretation.
Because the performed methylation assay was based on the quantita-
tive genotyping of C/T variation produced at CpG sites by bisulﬁte con-
version, we were unable to distinguish non-methylated cytosine from
thymine if there was a SNP at the interrogated CpG site. Likewise, if
there was a SNP at the guanine of the dinucleotide CpG, the CpG site
was lost. The 450K platform contains 4.3% of the interrogated CpG
sites harboring SNPs (Price et al., 2013), and the CpG panel that was de-
lineated in association with germline CDKN2A mutation displayed a
great enrichment of these SNP sites. This either could represent an epi-
genetic signature of these hereditary melanoma patients or surrogate
genetic markers. To answer this question, four of these CpGs harboring
SNPs sites were genotyped, all of themmapped at genes previously as-
sociated with melanoma: PLXNC1, a suppressor of melanoma progres-
sion (Chen et al., 2013; Paliwal et al., 2013; Scott et al., 2009), DFNA5,
a gene that contributes to resistance of melanoma to drug treatment
(Lage et al., 2001),MIB2, reported as suppressor of melanoma invasion
(Takeuchi et al., 2006), and TGFBR3, a candidate gene to melanoma sus-
ceptibility (Walker et al., 2004). Our data showed that the detected
methylation level at these sites inmelanoma patients and controls is di-
rectly associated with genetic variation.
To date, seven genome-wide association studies have investigated
the etiology of CDKN2A-negative familial melanoma (Amos et al.,
2011; Barrett et al., 2011; Bishop et al., 2009; Brown et al., 2008; Iles
et al., 2013;Macgregor et al., 2011; Teerlink et al., 2012), and the report-
ed SNPs do not overlap with our gene dataset. Genetic variants can also
inﬂuence the penetrance of CDKN2Amutations, such as those mapped
to the repair genes POLN and PRKDC (Liang et al., 2012), and MC1R
(Fargnoli et al., 2010). Further investigation is needed to determine
whether the panel of CpGs harboring SNPs detected in CDKN2A-
mutated melanoma patients inﬂuences the penetrance of the CDKN2A
mutations.
In conclusion, our results demonstrate that (a) the leukocytes of spo-
radicmelanomapatients exhibit a DNAhypomethylation pattern, possi-
bly related to the occurrence of cancer near the time of methylome
investigation, and that (b) melanoma patients carrying CDKN2Amuta-
tions display an epigenomic signature, which probably results fromunderlying SNPs. However, further studies in larger melanoma patient
cohorts are warranted to clarify the etiology and importance of this
signature.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yexmp.2014.09.009.
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